Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran QT Interval Study
NCT02170987Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2006
- Primary completion
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of dabigatran in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in mean time-matched QTc Interval at 3 hours. Started Mar 2006; status: completed.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02170987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170987.